Elraglusib/GnP Improves Survival in Metastatic Pancreatic Adenocarcinoma

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 15, 2026.

via HealthDay

WEDNESDAY, April 15, 2026 -- For patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), elraglusib, an inhibitor of GSK-3β, with gemcitabine plus nab-paclitaxel (GnP) improves overall survival compared with GnP alone, according to a study published online April 14 in Nature Medicine.

Devalingam Mahalingam, M.D., Ph.D., from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, and colleagues examined the efficacy and safety of elraglusib with GnP in patients with previously untreated mPDAC in a phase 2 study. Participants were randomly assigned to weekly elraglusib/GnP or GnP alone (155 and 78 patients, respectively, in the modified intent-to-treat population).

The researchers found that median overall survival improved by 2.9 months and the risk for death was decreased by 38 percent with elraglusib/GnP versus GnP alone as of the data cutoff on April 27, 2025 (median overall survival, 10.1 versus 7.2 months; hazard ratio, 0.62). One-year survival rates were 44.1 and 22.3 percent, respectively, for elraglusib/GnP and GnP alone. For elraglusib/GnP versus GnP alone, the most common grade 3 and greater treatment-emergent adverse events were neutropenia (52.3 versus 30.8 percent), anemia (25.2 versus 29.5 percent), and fatigue (16.8 versus 5.1 percent). In the elraglusib/GnP arm, baseline circulating immune-related factors were associated with improved survival. Increases in the intratumoral cytotoxic immune cell populations accompanied treatment.

"While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult-to-treat cancer is encouraging," Mahalingam said in a statement. "Given the novel mechanism of this drug, these findings raise the possibility that it could have broader application across other tumor types."

Several authors disclosed ties to biopharmaceutical companies, including Actuate Therapeutics, which is developing elraglusib and funded the trial.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-16 02:10

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords